Sunday, March 01, 2020 12:44:49 PM
That's false information. Company searching for ways to "scale up production."
“We believe Co-Diagnostics is the first U.S. company to receive a CE-marking for a coronavirus IVD, which is a testament to the quality of our platform. The rapid development of our COVID-19 test was made possible thanks to our proprietary design process and patented CoPrimer™ technology platform. We look forward to scaling up production to meet global demand with this regulatory clearance in place, and to obtaining approvals from other bodies that will allow us to further increase the reach of this invaluable diagnostic tool.”
“We believe Co-Diagnostics is the first U.S. company to receive a CE-marking for a coronavirus IVD, which is a testament to the quality of our platform. The rapid development of our COVID-19 test was made possible thanks to our proprietary design process and patented CoPrimer™ technology platform. We look forward to scaling up production to meet global demand with this regulatory clearance in place, and to obtaining approvals from other bodies that will allow us to further increase the reach of this invaluable diagnostic tool.”
New York Yankees and Duke Basketball
Recent CODX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 08:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 08:04:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 08:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 08:03:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 08:02:30 PM
- Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara • PR Newswire (US) • 05/26/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 12:00:36 PM
- Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 05/20/2026 02:54:00 AM
- Diagnostic Platform Jumps as Ebola Response Readiness Takes Center Stage • AllPennyStocks.com • 05/19/2026 03:04:00 PM
- Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX) • IH Market News • 05/19/2026 02:34:19 PM
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/18/2026 04:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:10:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:05:17 PM
- Co-Diagnostics Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/14/2026 08:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/12/2026 08:30:38 PM
- Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City • PR Newswire (US) • 05/08/2026 01:00:00 PM
- Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast • PR Newswire (US) • 04/30/2026 01:00:00 PM
- Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C. • PR Newswire (US) • 04/16/2026 01:00:00 PM
- Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany • PR Newswire (US) • 04/14/2026 01:00:00 PM
- Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah • PR Newswire (US) • 04/09/2026 01:00:00 PM
- Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City • PR Newswire (US) • 04/02/2026 01:00:00 PM
- This Diagnostics Company Is Advancing a Global Expansion Strategy, Positioning for Growth Phase • AllPennyStocks.com • 03/31/2026 09:59:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:10:33 PM
- Co-Diagnostics Reports Full Year 2025 Financial Results • PR Newswire (US) • 03/31/2026 08:01:00 PM
